Saturday - August 30, 2025

Category Archives: Pharmaceuticals & Biotech

Antisense Oligonucleotide Therapeutics Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insight 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Glioblastoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Glioblastoma Pipeline Insight, 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics … Continue reading →

Hepatitis B Virus Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Hepatitis B Virus Infection Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and … Continue reading →

AAV Vectors in Gene Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 250+ pipeline drugs in AAV Vectors in Gene Therapy pipeline landscape. It covers the AAV Vectors in Gene Therapy pipeline drug … Continue reading →

Schizophrenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Schizophrenia Pipeline Insights 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia therapeutics assessment … Continue reading →

Dry Eye Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Dry Eye Disease Market Key Dry Eye Disease companies developing novel therapies include Palatin Technologies, Aldeyra Therapeutics, ReGenTree/RegeneRx, Mimetogen, Alcon/Aerie, BRIM Biotechnology, Seikagaku, Mitotech, Senju Pharmaceutical, Sylentis/PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll/Daewoong, Redwood Pharma, OKYO Pharma, Glaukos, Oculis, and others. … Continue reading →

Tenosynovial Giant Cell Tumors Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Tenosynovial Giant Cell Tumors Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tenosynovial Giant Cell Tumors pipeline landscape. It covers the Tenosynovial Giant Cell Tumors pipeline drug profiles, including clinical and nonclinical … Continue reading →

Major depressive disorder Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Major depressive disorder Market According to DelveInsight, the Major Depressive Disorder Treatment Market Size in the 7MM was approximately USD 7,165 million in 2023. Major depressive disorder Market Summary According to DelveInsight, there were ~44 million diagnosed cases of Major … Continue reading →